"The other positive development is to see how well the Herceptin SubQ has picked up in Europe in a very short period of time, so less than a year in every major market. And you can see many of these key markets in both Europe and in Latin America already have between 40% and 50% total penetration of Herceptin in the marketplace. That's both metastatic and adjuvant. I think it speaks volumes to the convenience factor for patients and the convenience factors for hospitals and health care systems. And as I mentioned in previous reports, when we see hospitals switch or, in some cases, even countries, you literally see an entire switch of the Herceptin franchise within a health care system. And remember, the Herceptin SubQ, the MabThera SubQ that we received approval for and will be rolling out have additional patents associated with these as a way to secure Herceptin and MabThera vis-à-vis biosimilar competition outside the United States in this particular case."
From seekingalpha.com Roche transcript.